BUCCAL DELIVERY SYSTEM

Link for article: https://ijpsr.com/bft-article/an-overview-on-buccal-drug-delivery-system/?

view=fulltext

 Oral trans-mucosal drug delivery concerned with the systemic delivery of the drug
moiety via mucous membrane of the oral cavity.
 Buccal drug delivery systems interact with the mucus layer covering the mucosal
epithelial surface, and mucin molecules and increase the residence time of the dosage
form at the site of absorption.
 Oral trans-mucosal drug delivery can be subdivided into:
Sublingual delivery: floor of the mouth
Buccal delivery: lining of the cheek

Light microscopy reveals several distinct patterns of maturation in the epithelium of the human oral
mucosa based on various regions of the oral cavity.

The distinctive layers of the oral mucosa are the:

 Epithelium (Act as barrier for lipophilic drugs)

 Lamina Propria (Act as barrier for hydrophilic drugs)
 Basement membrane, and
 Submucosa
 The oral cavity is lined with the epithelium, below which lies the supporting basement
membrane tissues.

The epithelium, as a protective layer for the tissues beneath, is divided into

(a) Non-keratinized surface in the mucosal lining of the soft palate, the ventral surface of the
tongue, the floor of the mouth, alveolar mucosa, vestibule, lips, and cheeks, and

(b) Keratinized epithelium which is found in the hard palate and non-flexible regions of the
oral cavity.

It contains following layers: Stratum distendum, Stratum filamentosum, Stratum suprabasale

and Stratum basale.

40-50 cell thick & is major barrier for

Lamina Propria: Constitutes of a continuous sheet of connective tissue containing collagen,
elastic fibers and cellular components in a hydrated ground substance. It also carries blood
capillaries and nerve fibers that serve the mucosa. It is through the blood vessels in the
lamina propria that drug moieties can gain entry to the systemic circulation.

Submucosa: This is a layer of loose connective tissue that supports the epithelium and also
contains blood vessels, lymphatics and nerves.
Environment: Biochemistry of mucin, mucous composition

Drug absorption pathways

The drug transport mechanism through the buccal mucosa involves two major routes:
 Transcellular (intracellular or directly through the cells)

 Paracellular (intercellular or through the spaces between the cells) pathways

In general, for many drugs, permeation across the buccal epithelium is thought to be through the
Paracellular route by passive diffusion. This pathway is favored especially by hydrophilic
drugs such as peptides/proteins which dissolve more readily in the aqueous fluids filling the
intercellular spaces.
The transcellular pathway, in contrast, involves drugs permeating the cell membrane and going
through the cell to then penetrate the opposite cell membrane and into the next cell, and so on.
An example of a drug known to penetrate via the transcellular pathway is fentanyl.
It is feasible that some drugs may penetrate via both pathways and this may occur with drugs
that have approximately balanced hydrophobic and hydrophilic properties, with a slight
predominance of hydrophobicity. Such drugs will usually penetrate the fastest.
It can readily be seen that the transcellular pathway is a more direct pathway, with drugs tending
to move directly across the cell layers with little lateral diffusion. For the paracellular pathway,
the drug moves in a tortuous fashion around the cells, thus this is a longer pathway.
Caffeine is an example of a drug absorbed via the paracellular route and it is used as a marker of
paracellular absorption.
While the transcellular route is more direct, the drug has to traverse the lipophilic cell membrane,
then the hydrophilic interior of the cell before passing through two cell membranes to reach the
cytoplasm of the next cell.
Therefore, the predominantly hydrophobic drug should have some hydrophilicity if absorption
into the systemic circulation is required. If the drug is extremely hydrophobic, there would be a
tendency for it to be retained in the more hydrophobic components of the mucosal tissue, such as
the cell membranes of the superficial epithelial layers, and not reach the blood circulation in
significant amounts.
This, of course, would be a desirable feature for a topical effect (e.g., anti-inflammatory action)
but not if a systemic effect is desired.
 Formulation Design

Pharmaceutical considerations: Great care needs to be exercised while developing a safe and
effective buccal adhesive drug delivery device.

Physiological Considerations
Physiological considerations such as; texture of buccal mucosa, thickness of the mucus layer, its
turn over time, effect of saliva and other environmental factors are to be considered in designing
the dosage forms.
Saliva contains moderate levels of esterases, carbohydrases, and phosphatases that may degrade
certain drugs.
Although saliva secretion facilitates the dissolution of drug, involuntary swallowing of saliva
also affects its bioavailability.

Pharmacological Considerations
 Drug absorption depends on the partition coefficient of the drugs.
 Generally, lipophilic drugs absorb through the transcellular route, whereas; hydrophilic
drugs absorb through the paracellular route.
 Chemical modification may increase drug penetration through buccal mucosa.
 Residence time and local concentration of the drug in the mucosa, the amount of drug
transported across the mucosa into the blood are the responsible factors for local or
systemic drug delivery.
 Optimization by a suitable formulation design fastens drug release from the dosage form
and taken up by the oral mucosa.

Basic Components for BDDS

 API
 Bioadhesive Polymers
 Permeation Enhancer

Buccal adhesive drug delivery systems with the size 1–3 sq.cm and a daily dose of 25 mg or less
are preferable. The maximal duration of buccal delivery is approximately 4–6 hrs. To make such
dosage form following components are required.
Bioadhesive Polymers
 Bioadhesive formulations use polymers as the adhesive component.
 These formulations are often water soluble and when in a dry form attract water from the
biological surface and this water transfer leads to a strong interaction.
 It also forms viscous liquids when hydrated with water that increases their retention time
over mucosal surfaces and may lead to adhesive interactions.
  They should possess certain physicochemical features including hydrophilicity, numerous
hydrogen bond-forming groups, and flexibility for interpenetration with mucus and
epithelial tissue, and visco-elastic properties.

Polymers in Buccal Drug Delivery

 Polymers remain the most versatile class of biomaterials, being extensively applied in
medicine and biotechnology as well as in the food and cosmetic industries.
 Applications include surgical devices, implants and supporting materials (for e.g.
artificial organs, prostheses and sutures), drug–delivery systems with different routes of
administration and design, carriers of immobilized enzymes and cells, biosensors,
components of diagnostic assays, bioadhesives, ocular devices, and materials for
orthopedic applications.
Classifying the properties of polymers for their selection as biomaterials is challenging, because
a wide variety of materials are available for a particular application (e.g. surgery, drug delivery)
and no single, simple set of methods can be used to characterize polymers.
Polymers used as biomaterials can be naturally occurring, synthetic or a combination of both.
Polymers that adhere to the mucin-epithelial surface can be conveniently divided into three broad
categories:
 Polymers that become sticky when placed in water and owe their bioadhesion to
stickiness.
 Polymers that adhere through non-specific, non-covalent interactions, which are
primarily electrostatic in nature.
 Polymers that bind to specific receptor sites on the cell surface.

Characteristics of an Ideal Polymer for Mucoadhesive Drug Delivery System

An ideal polymer should possess the following characteristics:
 The polymer and its degradation products should be non-toxic and non-absorbable from
the GI tract.
 It should be non-irritant to the mucous membrane.
 It should preferably form a strong non-covalent bond with mucin-epithelial cell surfaces.
 It should preferably adhere quickly to moist tissue and should possess some site
specificity.
 It should allow easy incorporation of the drug and offer no hindrance to its release.
  The polymer must not decompose on storage or during the shelf life of the dosage form.
 The cost of the polymer should not be high so that the prepared dosage form remains
competitive.
Add examples

Permeation Enhancer
 Membrane permeation is the limiting factor for many drugs in the development of buccal
adhesive delivery devices.
 The epithelium that lines the buccal mucosa is a very effective barrier to the absorption of
drugs.
 Substances that facilitate the permeation through buccal mucosa are referred as
permeation enhancers.
 As most of the penetration enhancers were originally designed for purposes other than
absorption enhancement, a systemic search for safe and effective penetration enhancers
must be a priority in drug delivery.
 The goal of designing penetration enhancers, with improved efficacy and reduced toxicity
profile is possible by understanding the relationship between enhancer structure and the
effect induced in the membrane and of course, the mechanism of action.
 However, the selection of enhancer and its efficacy depends on the physicochemical
properties of the drug, site of administration, nature of the vehicle and other excipients. In
some cases, usage of enhancers in combination has shown synergistic effect than the
individual enhancers.
 The efficacy of enhancer in one site is not same in the other site because of differences in
cellular morphology, membrane thickness, enzymatic activity, lipid composition and
potential protein interactions are structural and functional properties.
 Penetration enhancement to the buccal membrane is drug specific.
 Effective penetration enhancers for transdermal or intestinal drug delivery may not have
similar effects on buccal drug delivery because of structural differences; however,
enhancers used to improve drug permeation in other absorptive mucosae improve drug
penetration through buccal mucosa.
 These permeation enhancers should be safe and nontoxic, pharmacologically and
chemically inert, non-irritant, and non-allergenic.
Example: Cyclodextrin, benzalkonium chloride, dextran sulfate, lauric acid, menthol, sodium
EDTA, sodium salicylate.

Drug of Choice (API)

Choice of drug for buccal formulation is property specific.
 Molecular weight of 1000 Dalton or less.
 Should possess lipophilic and hydrophilic properties.
 Should have low melting point.
 Should be potent.
 T1/2 should be shorter.
 Non-irritant to oral mucosa.
 Drug degraded in GI tract
Buccal Mucoadhesive Dosage Forms
Buccal mucoadhesive dosage forms can be categorized into three types based on their geometry:
Type I:
It is a single layer device with multidirectional drug release. This type of dosage form suffers
from significant drug loss due to swallowing.
Type II:
It is a device in which an impermeable backing layer is superimposed on top of the drug loaded
bioadhesive layer, creating a double-layered device and preventing drug loss from the top surface
into the oral cavity.
Type III:
It is a unidirectional drug release device, from which drug loss is minimal, since the drug is
released only from the side adjacent to the buccal mucosa. This can be achieved by coating every
face of the dosage form, except the one that is in contact with the buccal mucosa.